drugset / Trial / NCT05398913
Effects of Rimonabant on Walking Abilities in Incomplete Spinal Cord Injury
RandomizedCrossoverQuadruple-blindTreatment
Summary
Randomized placebo-controlled safety and feasibility study with crossover design (3 arms). Placebo or Rimonabant 2.5mg or Rimonabant 5mg will be administered for 5 days. Exploratory efficacy will be tested using six-min walking test.
Timeline
- Start
- 2021-05-12
- Primary completion
- 2022-06-07
- Completion
- 2022-06-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Rimonabant | Small molecule | 2.5 mg | — |
| Comparator | Rimonabant | Small molecule | 5 mg | — |